bullish
Giant Biogene Placement - Has Been Doing Well but Doesn’t Need the Cash
249 Views16 May 2024 18:55
Giant Biogene (2367 HK) aims to raise up to US$205m via a top-up placement. In this note, we talk about the deal dynamics and run the deal through our ECM framework.
What is covered in the Full Insight:
- Giant Biogene's recent performance
- Analysts' take on the stock
- The company's FY23 results
- Deal terms
- Concluding thoughts
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- ECM Weekly (3rd June 2024) - Shift Up, QuantumPharm, Telix, Sompo, ASMedia, Exedy, Barito, Zomato03 Jun 2024
- ECM Weekly (27th May 2024) - Renesas, AUB, Modec, Tata Tech, MUFG, Shift Up, Novelis, Shulan27 May 2024
- ECM Weekly (20th May 2024) -Lalatech, Go Digit, Aadhar, TBO Tek, Ecopro, Nexus, Modec, Hyundai Heavy20 May 2024
- Giant Biogene Placement - Has Been Doing Well but Doesn’t Need the Cash16 May 2024
- Giant Biogene (2367 HK) – Pioneer in Recombinant Collagen Market27 Nov 2023
- 2024 High Conviction - Giant Biogene - Growth Rate Keeps Moving Higher23 Nov 2023
- Giant Biogene IPO Lock-Up - US$1.7bn Lockup Release Will Increase Free Float by 14x02 May 2023
x